B
SKYE icon

Braidwell’s Skye Bioscience SKYE Stock Holding History

Braidwell’s Portfolio SKYE Stock Details SKYE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-103,217
Closed -$1.31M – 64
2025
Q1 		$1.31M Hold
103,217
– – 0.05% 63
2024
Q4 		$2.34M Buy
+103,217
New +$3.45M 0.07% 70

Other funds holding SKYE

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Braidwell's SKYE Position: Q2 2025 in Review

Braidwell sold out of Skye Bioscience (SKYE) in Q2 2025, closing a stake of 103,217 shares — an estimated $1.31M sold.

Braidwell first reported a position in SKYE in Q4 2024 and held it in 2 quarters. The position peaked at $2.34M in Q4 2024. 55 funds tracked by Wall St. Rank hold SKYE as of Q2 2025.

  • Braidwell reported no remaining Skye Bioscience position as of Q2 2025 after selling out during the quarter.
  • Braidwell sold 103,217 Skye Bioscience shares in Q2 2025, an estimated $1.31M.
  • Braidwell first reported a position in Skye Bioscience in Q4 2024 and held it in 2 quarters.
  • Braidwell's Skye Bioscience position peaked at $2.34M in Q4 2024.
  • 55 funds tracked by Wall St. Rank held Skye Bioscience as of Q2 2025.

Based on Braidwell's 13F filing for Q2 2025, filed 14 Aug 2025.